drugset

drugset / Trial / NCT07037901

A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

NCT07037901 ↗

Phase 2 Recruiting 405 enrolled Inmagene LLC

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of different dose regimens of IMG-007, compared to placebo.

Timeline

Start: 2025-06-17
Primary completion: 2027-12
Completion: 2028-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	IMG-007	Unknown	—	Subcutaneous

Indications